Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer



Status:Recruiting
Conditions:Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:April 5, 2016

Use our guide to learn which trials are right for you!

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

This randomized phase II trial studies how well cabozantinib s-malate, crizotinib,
savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread
from where it started to nearby tissue or lymph nodes or to other places in the body.
Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating
patients with kidney cancer compared to sunitinib malate.

PRIMARY OBJECTIVES:

I. To compare progression-free survival (PFS) in patients with metastatic papillary renal
cell carcinoma (mPRCC) treated with sunitinib malate (sunitinib) to PFS in patients with
mPRCC treated with MET kinase inhibitors.

SECONDARY OBJECTIVES:

I. To compare Response Evaluation Criteria in Solid Tumors (RECIST) response rate (RR;
defined as the combined rate of confirmed and unconfirmed partial response [PR] and complete
response [CR]) in patients with mPRCC treated with sunitinib to RR in patients treated with
putative MET inhibitors.

II. To compare overall survival (OS) in patients with mPRCC treated with sunitinib to OS in
patients with mPRCC treated with putative MET inhibitors.

III. To compare the safety profile of sunitinib and putative MET inhibitors in patients with
mPRCC.

TRANSLATIONAL OBJECTIVES:

I. To evaluate the prognostic and predictive value of MET mutations, MET copy number or other
markers of MET signaling in patients with mPRCC treated with putative MET inhibitors.

OUTLINE: Patients are randomized to 1 of 4 treatment arms. As of 12/5/18, patients will only
be randomized to Arm I or Arm II.

ARM I: Patients receive sunitinib malate orally (PO) on days 1-28.

ARM II: Patients receive cabozantinib s-malate PO on days 1-42.

ARM III (CLOSED TO ACCRUAL 12/5/18): Patients receive crizotinib PO twice daily (BID) on days
1-42.

ARM IV (CLOSED TO ACCRUAL 12/5/18): Patients receive savolitinib PO on days 1-42.

In all arms, courses repeat every 42 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up for 3 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed papillary histology renal
cell carcinoma which is metastatic or locally advanced disease not amenable to
surgical resection; (NOTE: a designation of type I or type II should be made by the
local pathologist if possible); mixed histologies containing type I or type II will be
allowed provided that they contain >= 50% of the papillary component

- Patients must also have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension; disease X-rays, scans or physical
examinations used for tumor measurement must have been completed within 28 days prior
to registration; if there is clinical suspicion for bone metastases at the time of
enrollment (at the discretion of the investigator), bone scan should be performed at
baseline (within 42 days prior to registration); all disease must be assessed and
documented on the Baseline Tumor Assessment form

- Patients with a history of treated brain metastases who are asymptomatic and have not
received steroid therapy in the 14 days prior to registration are eligible;
anti-seizure medications are allowed provided they are non-enzyme inducing (e.g.
topiramate, levetiracetam, gabapentin)

- Patients must not have cavitating pulmonary lesions; patients must not have tumor
invading the gastrointestinal (GI) tract or evidence of endotracheal or endobronchial
tumor within 28 days prior to registration

- Patients may have received prior surgery; at least 28 days must have elapsed since
surgery and patient must have recovered from any adverse effects of surgery

- Patients may have received up to one prior systemic therapy for advanced or metastatic
renal cell carcinoma with the exception of another VEGF inhibitor Food and Drug
Administration (FDA)-approved for advanced RCC (i.e., pazopanib, bevacizumab,
sorafenib or axitinib); if a patient develops metastatic disease within six months of
discontinuation of adjuvant therapy, this will constitute one prior systemic therapy
for advanced or metastatic renal cell carcinoma (RCC); if a patient develops
metastatic disease and more than six months has elapsed since discontinuation of
adjuvant therapy, this will not constitute prior systemic therapy for advanced or
metastatic RCC; patients may have also received prior immunotherapy; patients must not
have received a MET/hepatocyte growth factor (HGF) inhibitor or sunitinib as prior
therapy; at least 14 days must have elapsed since completion of prior systemic
therapy; patients must have recovered from all associated toxicities at the time of
registration

- Patients may have received prior radiation therapy, but must have measurable disease
outside the radiation port; at least 14 days must have elapsed since completion of
prior radiation therapy; patients must have recovered from all associated toxicities
at the time of registration

- Patients must not be taking, nor plan to take while on protocol treatment, strong
CYP3A4 inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT,
fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone,
nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipravavir/RIT, or
voriconazole); strong CYP3A4 inducers (e.g. avasimibe, phenytoin, rifampin,
rifabutin); potent inhibitors of CYP1A2 (e.g. ciprofloxacin); and/or drugs known to be
CYP3A4 substrates with a narrow therapeutic range (e.g., diergotamine, ergotamine)
within 14 days prior to randomization; moderate inhibitors or inducers of isoenzyme
CYP3A4 should be avoided, but if necessary can be used with caution

- Patients must not be receiving or planning to receive any other investigational agents

- Patients must have a complete physical examination and medical history within 28 days
prior to registration

- Patients must have a Zubrod performance status of 0 - 1

- White blood cell count (WBC) >= 2,000/mcL (must be obtained within 28 days prior to
registration)

- Absolute neutrophil count (ANC) >= 1,000/mcL (must be obtained within 28 days prior to
registration)

- Platelet count >= 75,000/mcL (must be obtained within 28 days prior to registration)

- Serum bilirubin =< 1.5 x institutional upper limits of normal (ULN) (must be obtained
within 28 days prior to registration)

- Serum transaminase (serum glutamic oxaloacetic transaminase [SGOT]/aspartate
aminotransferase [AST] and serum glutamate pyruvate transaminase [SGPT]/alanine
aminotransferase [ALT]) must be =< 2.5 x the institutional ULN unless the liver is
involved with the tumor, in which case serum transaminase (SGOT/SGPT) must be =< 5 x
the institutional ULN (must be obtained within 28 days prior to registration)

- Serum creatinine must be =< 2 x the institutional ULN OR creatinine clearance (either
measured or calculated) must be > 30 mL/min (must be obtained within 28 days prior to
registration)

- Patients must not have any clinical evidence of congestive heart failure (CHF)
(specifically, New York Heart Association [NYHA] class III [moderate] or class IV
[severe]) at the time of registration; baseline echocardiogram within 28 days of
registration must demonstrate an ejection fraction (EF) >= 50%; patients must have
corrected QT (QTc) interval < 500 msec on prestudy electrocardiogram (EKG) and no
known history of congenital long QT syndrome; patients must not have experienced
unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke
(transient ischemic attack [TIA] or other ischemic event) within 3 months prior to
registration and not have experienced myocardial infarction or thromboembolic event
requiring anticoagulation within 6 months of registration; prestudy EKG must be
obtained within 28 days prior to registration

- Baseline urinalysis should show urine protein < 3+ and must be obtained within 28 days
prior to registration; if urine protein is 3+ or greater, then urine protein by 24
hour collection must show less than 3 grams of protein

- Patients must not have inadequately controlled hypertension; patients must have
documented blood pressures of systolic blood pressure (SBP) < 150 and diastolic blood
pressure (DBP) < 90 within 14 days of starting randomization; blood pressure
medications (any number) are permitted

- Patients must be able to take oral medications (i.e., swallow pills whole); patients
must not have gastrointestinal tract disease resulting in an inability to take oral
medication or a requirement for intravenous (IV) alimentation, prior surgical
procedures that could in the opinion of the treating investigator affect absorption,
or active peptic ulcer disease; patients with intractable nausea or vomiting are not
eligible

- Patients must not have had any clinically-significant GI bleeding within 6 months
prior to registration and patients must not have a GI disorder which (at the
discretion of the investigator) bears a high risk of perforation or fistula; examples
of this include (but are not limited to) Crohn's disease or tumor with transmural
extension through the gastrointestinal lining

- Patients must not have had hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within
3 months prior registration

- Patients must not demonstrate any other signs indicative of pulmonary hemorrhage
within 3 months prior to registration

- Patient's baseline imaging must not indicate the presence of tumor invading or
encasing any major blood vessels

- Patients must not have any unresolved wounds from previous surgery

- Albumin, alkaline phosphatase, bicarbonate, blood urea (BUN), chloride, glucose,
phosphorus, and total protein must be assessed within 28 days of registration

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for 3 years; men receiving
active surveillance for prostate cancer may also be enrolled

- Due to the unknown effects of the study drugs, patients must not be pregnant or
nursing; women/men of reproductive potential must have agreed to use an effective
contraceptive method while receiving study drug and for three months after last dose
of study drug; a woman is considered to be of "reproductive potential" if she has had
menses at any time in the preceding 12 consecutive months; in addition to routine
contraceptive methods, "effective contraception" also includes heterosexual celibacy
and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal
ligation; however, if at any point a previously celibate patient chooses to become
heterosexually active during the time period for use of contraceptive measures
outlined in the protocol, he/she is responsible for beginning contraceptive measures

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible because of the potential for pharmacokinetic interactions with
cabozantinib, crizotinib, savolitinib or sunitinib; in addition these patients are at
increased risk of lethal infections when treated with marrow suppressive therapy;
appropriate studies will be undertaken in patients receiving combination
antiretroviral therapy when indicated

- Patients must have tissue available and be willing to submit for independent
pathologic review in order to classify type I versus type II papillary disease

- Patients must be offered the opportunity to participate in specimen banking for future
translational medicine studies

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines

- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system.
We found this trial at
566
sites
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Richard C. Lauer
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Robert Dreicer
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Sumanta K. Pal
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Bagi R. Jana
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: John C. Henegan
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Robert A. Figlin
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Christopher W. Ryan
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: John Sarantopoulos
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-487-7447
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-678-9000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-539-2273
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Richard C. Lauer
Phone: 505-925-0366
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Bruce G. Redman
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
?
mi
from
Asheville, NC
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Yujie Zhao
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
?
mi
from
Aventura, FL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Primo N. Lara
Phone: 661-323-4673
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Paul Celano
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Michael A. Carducci
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Leonard J. Appleman
Phone: 412-647-8073
?
mi
from
Beaver, PA
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
?
mi
from
Boardman, OH
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Gretchen A. Gignac
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 650-696-4487
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Calgary, Alberta
Principal Investigator: Daniel Y. Heng
Phone: 403-521-3433
?
mi
from
Calgary,
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Michael B. Lilly
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials